Sobi

News

Sobi adds rare lymphoma drug with $580m Innate tie-up

Sobi chief executive Guido Oelkers is preparing his exit, but is still cutting deals, licensing a lymphoma drug from Innate for up to $580m.

News

Sobi's long-serving CEO Guido Oelkers to step down

After nearly a decade in the role, Guido Oelkers is stepping down as chief executive of Sobi to take the top job at BioNTech.

News

Arthrosi drug trial in gout delivers for new owner Sobi

Sobi's $1.5 billion takeover of Arthrosi at the end of 2025 has started to pay off, with a positive phase 3 trial for gout therapy pozdeutinurad.

News

Sobi pays $1.5bn for Arthrosi to grow in gout

Sobi has hit the acquisition trail with a deal to buy Arthrosi Therapeutics for up to $1.5 billion, adding a drug in late-stage testing for gout.

News

UK haemophilia A patients get once-weekly treatment option

A long-acting Factor VIII replacement therapy for haemophilia A from Sobi and Sanofi has been recommended for use by the NHS.

News

11 blockbuster drugs to look out for in 2025

Clarivate has revealed 11 drugs due to launch in 2025 that could top $1 billion in annual sales or be clinical 'game changers' in the next five years.

Sobi adds rare lymphoma drug with $580m Innate tie-up

Sobi's long-serving CEO Guido Oelkers to step down

Arthrosi drug trial in gout delivers for new owner Sobi

Sobi pays $1.5bn for Arthrosi to grow in gout

UK haemophilia A patients get once-weekly treatment option

11 blockbuster drugs to look out for in 2025

Vogenx surpasses expectations with $81M IPO

Discover a new era of healthcare panel engagement: Grounded ...

Sobi

Editor's Picks